203 related articles for article (PubMed ID: 28347318)
1. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
[TBL] [Abstract][Full Text] [Related]
2. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
3. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
Daley P; Louie T; Lutz JE; Khanna S; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
J Antimicrob Chemother; 2017 Dec; 72(12):3462-3470. PubMed ID: 28961905
[TBL] [Abstract][Full Text] [Related]
4. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
[TBL] [Abstract][Full Text] [Related]
5. Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.
Citron DM; Tyrrell KL; Dale SE; Chesnel L; Goldstein EJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2069-74. PubMed ID: 26787687
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Roberts T; Kokai-Kun JF; Coughlin O; Lopez BV; Whalen H; Bristol JA; Hubert S; Longstreth J; Lasseter K; Sliman J
Clin Drug Investig; 2016 Sep; 36(9):725-734. PubMed ID: 27283946
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of surotomycin for the treatment of Clostridium difficile.
Knight-Connoni V; Mascio C; Chesnel L; Silverman J
J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
9. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
[TBL] [Abstract][Full Text] [Related]
12. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
Vickers R; Robinson N; Best E; Echols R; Tillotson G; Wilcox M
BMC Infect Dis; 2015 Feb; 15():91. PubMed ID: 25880933
[TBL] [Abstract][Full Text] [Related]
14. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With
Boix V; Fedorak RN; Mullane KM; Pesant Y; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
Open Forum Infect Dis; 2017; 4(1):ofw275. PubMed ID: 28480267
[TBL] [Abstract][Full Text] [Related]
15. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
[TBL] [Abstract][Full Text] [Related]
17. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
[TBL] [Abstract][Full Text] [Related]
18. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
19. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.
Lomeli BK; Galbraith H; Schettler J; Saviolakis GA; El-Amin W; Osborn B; Ravel J; Hazleton K; Lozupone CA; Evans RJ; Bell SJ; Ochsner UA; Jarvis TC; Baqar S; Janjic N
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685472
[TBL] [Abstract][Full Text] [Related]
20. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
Hodges MR; Ople E; Wedel P; Shaw KJ; Jakate A; Kramer WG; Marle SV; van Hoogdalem EJ; Tawadrous M
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0162322. PubMed ID: 36988461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
